Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP: Biology and management of bladder cancer. N Engl J Med. 1990, 322 (16): 1129-1138. 10.1056/NEJM199004193221607.
Article
CAS
PubMed
Google Scholar
Masood S, Sriprasad S, Palmer JH, Mufti GR: T1G3 bladder cancer–indications for early cystectomy. Int Urol Nephrol. 2004, 36 (1): 41-44.
Article
CAS
PubMed
Google Scholar
Lebret T, Watson RW, Molinie V, Poulain JE, O'Neill A, Fitzpatrick JM, Botto H: HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol. 2007, 51 (1): 161-166. 10.1016/j.eururo.2006.06.006. discussion 166–167
Article
CAS
PubMed
Google Scholar
Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol. 1995, 6 (2): 113-126.
CAS
PubMed
Google Scholar
Soloway MS, Lopez AE, Patel J, Lu Y: Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer. 1994, 73 (7): 1926-1931. 10.1002/1097-0142(19940401)73:7<1926::AID-CNCR2820730725>3.0.CO;2-Q.
Article
CAS
PubMed
Google Scholar
Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Ponten F, Johannesson H, Smaragdi K, Frantz C: High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. 2011, 5 (11–12): 624-635.
Article
CAS
PubMed
Google Scholar
Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S: Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2009, 22 (12): 1564-1574. 10.1038/modpathol.2009.124.
Article
Google Scholar
Jonsson L, Bergman J, Nodin B, Manjer J, Ponten F, Uhlen M, Jirstrom K: Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmo Diet and Cancer Study. J Transl Med. 2011, 9: 114-10.1186/1479-5876-9-114.
Article
PubMed
PubMed Central
Google Scholar
Jonsson L, Gaber A, Ulmert D, Uhlen M, Bjartell A, Jirstrom K: High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol. 2011, 6: 91-10.1186/1746-1596-6-91.
Article
PubMed
PubMed Central
Google Scholar
Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 2010, 8: 78-10.1186/1479-5876-8-78.
Article
PubMed
PubMed Central
Google Scholar
Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K: RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Translational oncology. 2011, 4 (4): 212-221.
Article
PubMed
PubMed Central
Google Scholar
Sauter GAF, Amin MB: Noninvasive urothelial neoplasias; WHO classification of noninvasive papillary urothelial tumours. A World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Edited by: In Elbe JN EJ, Sesterhenn I. 2004, Lyon: IARCC
Google Scholar
Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG: Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene. 2008, 27 (33): 4544-4556. 10.1038/onc.2008.97.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Buhrer C: The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res. 2010, 67 (1): 35-41. 10.1203/PDR.0b013e3181c13326.
Article
CAS
PubMed
Google Scholar
Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J: DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl. 2007, 30 (4): 282-291. 10.1111/j.1365-2605.2007.00772.x. discussion 291
Article
CAS
PubMed
Google Scholar
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005, 434 (7035): 864-870. 10.1038/nature03482.
Article
CAS
PubMed
Google Scholar
Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992, 10 (7): 1066-1073.
PubMed
Google Scholar
Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T: A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012, 62 (3): 523-533. 10.1016/j.eururo.2012.05.048.
Article
CAS
PubMed
Google Scholar
Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D: ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013, 63 (1): 58-66. 10.1016/j.eururo.2012.08.010.
Article
PubMed
Google Scholar
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000, 18 (17): 3068-3077.
CAS
PubMed
Google Scholar
Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A: Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009, 27 (3): 295-300. 10.1007/s00345-009-0395-z.
Article
CAS
PubMed
PubMed Central
Google Scholar
Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR: Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol. 2007, 127 (6): 946-953. 10.1309/XUVXFXMFPL7TELCE.
Article
PubMed
Google Scholar